Investor Education Webinar
Rhea-AI Summary
Telix (ASX: TLX, NASDAQ: TLX) invites investors to an educational webinar titled The Future of Prostate Imaging: What do physicians want? featuring KOLs discussing PSMA-PET/CT innovations for prostate cancer.
The webcast is scheduled EST: Wednesday March 4, 2026 at 5:30 p.m.; AEDT: Thursday March 5, 2026 at 9:30 a.m. The event will run approximately one hour and requires registration via the company's webcast link.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Only one biotech peer in the momentum scanner, SLNO, showed an upside move of about 6.22% with no associated news, while other listed peers had mixed, modest moves. This points to stock-specific dynamics for TLX around this webinar update rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Conference participation | Positive | +14.6% | Upcoming participation in Oppenheimer and TD Cowen investor conferences with webcasts. |
| Feb 19 | Earnings results | Positive | +14.6% | FY 2025 results showing strong revenue growth, EBITDA, and FY 2026 revenue guidance. |
| Feb 17 | Regulatory filing | Positive | -0.2% | Submission of European MAA for TLX101-Px for glioma imaging across major EU markets. |
| Feb 03 | Results webcast | Neutral | -0.1% | Notification of timing and access details for the FY 2025 results investor webcast. |
| Jan 20 | Preliminary results | Positive | -0.4% | Unaudited FY 2025 revenue in line with upgraded guidance and Gozellix-driven growth milestones. |
Recent history shows strong positive price reactions to financial updates and guidance, while regulatory milestones have seen muted or slightly negative moves, and pure event/webcast notices have generated minimal price impact.
Over the last few months, Telix has reported significant commercial growth, with FY 2025 revenue reaching the US$803–804M range and guidance for FY 2026 implying continued expansion. Regulatory progress included a European MAA for TLX101-Px. Investor-facing events—such as webcasts and conference appearances—have typically produced limited price movement compared to earnings and guidance. This webinar invite fits the pattern of informational investor outreach rather than a fundamental catalyst.
Market Pulse Summary
This announcement highlights an investor-focused webinar featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer, scheduled for March 4–5, 2026. It follows a series of recent financial and regulatory updates that have been more consequential for the share price. Investors may view this as an educational touchpoint on Telix’s clinical domain rather than a direct financial catalyst, while continuing to monitor future earnings and regulatory milestones.
Key Terms
psma-pet/ct medical
urology medical
AI-generated analysis. Not financial advice.
The Future of Prostate Imaging: What do physicians want?
MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to discuss a physician’s perspective on innovations in PSMA-PET/CT imaging for prostate cancer.
Speakers:
- Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Executive Chairman and Chief Medical Officer at the Melbourne Theranostic Innovation Centre (MTIC);
- Paul Yonover, MD, FACS, Chief Data Officer and Director of Clinical Navigation at UroPartners, a division of The Specialty Alliance; Chief of Urology at Ascension Saint Joseph Hospital, Chicago; and
- Darren Patti, PharmD, Telix Group Chief Operating Officer.
The webinar will be moderated by David N. Cade, MD, Telix Group Chief Medical Officer.
The webinar will be held on:
EST: Wednesday March 4, 2026, 5:30 p.m.
AEDT: Thursday March 5, 2026, 9:30 a.m.
The event will run for approximately one hour.
Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/n87mam6r
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including the planned NDA resubmission for TLX101-Px and the planned BLA resubmission for TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
FAQ
When is the Telix (TLX) investor education webinar on prostate imaging scheduled?
How can investors register for the Telix (TLX) webinar on March 4–5, 2026?
Who are the keynote speakers for the Telix (TLX) webinar on PSMA-PET/CT imaging?
What topics will Telix (TLX) cover during the prostate imaging webinar?
How long is the Telix (TLX) investor webinar and is it live or pre-recorded?
Is the Telix (TLX) webinar intended for investors, clinicians, or both?
